CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Premetrexed (Alimta)drug
Likely dose
Pemetrexed 500 mg/m² IV every 3 weeksAI-extracted
Key inclusion· 5
  • ✓Histologically confirmed invasive, recurrent or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery
  • ✓Measurable disease with at least one bidimensional measurable lesion documented within 6 weeks prior to registration
  • ✓ECOG performance status 0 or 1
  • ✓Adequate organ function: bilirubin ≤1.5, creatinine clearance ≥45, granulocytes ≥1500, platelets ≥100K
Key exclusion· 4
  • ✕Acute intercurrent infection or complications
  • ✕Pregnancy or lactation
  • ✕Inability to interrupt aspirin or NSAIDs for 5 days (8 days for long-acting agents)
  • ✕Clinically relevant third-space fluid collections that cannot be controlled by procedure

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00198133
NCT00198133Phase 2Completed
CompareCT.gov

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

Patrick Joseph Loehrer Sr.·interventional·Posted Sep 20, 2005·Updated Jul 22, 2019

In Brief

A Phase 2 clinical trial evaluating Premetrexed (Alimta) for Thymoma and Thymic Carcinoma. Completed, enrolled 27 participants across 1 site.

Detailed Summary

To study the efficacy of Alimta as a single agent in thymic cancers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThymoma, Thymic Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartJan 1, 2005
Primary CompletionDec 1, 2006
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.8 years ago

Interventions

Premetrexed (Alimta)drug

Pemetrexed will be 500 mg/m2 IV every 3 weeks